Literature DB >> 32272444

Longitudinal ultra-high field MRI of brain lesions in neuromyelitis optica spectrum disorders.

Sanjeev Chawla1, Yulin Ge2, Jens Wuerfel3, Shadi Asadollahi4, Suyash Mohan4, Friedemann Paul5, Tim Sinnecker5, Ilya Kister6.   

Abstract

BACKGROUND: In neuromyelitis optica spectrum disorder (NMOSD), clinical disability in NMOSD patients is relapse-related and progressive phase is rare. This observation raises the question whether there is any radiographic disease activity. The aim of present study was to determine the longitudinal changes in cerebral lesion number, lesion size, lesion-to-venule relationship, and morphological patterns of lesions in NMOSD using multiparametric 7T MR imaging. We also aimed to assess brain volume changes in NMOSD.
METHODS: A cohort of 22 patients with NMOSD underwent high-resolution 3D-susceptibility weighted imaging (SWI) and 2D-gradient-echo (GRE-T2*) weighted imaging on 7T MRI of brain at baseline and after ~2.8 years of follow-up. Morphologic imaging characteristics, and signal intensity patterns of lesions were recorded at both time points. Lesions were classified as "iron-laden" if they demonstrated hypointense signal on GRE-T2* images and/or SWI as well as hyperintense signal on quantitative susceptibility mapping (QSM). Lesions were considered "non-iron-laden" if they were hyperintense on GRE-T2*/SWI and isointense or hyperintense on QSM. Additionally, fractional brain parenchymal volume (fBPV) was computed at both time points.
RESULTS: A total of 169 lesions were observed at baseline. At follow-up, 6 new lesions were found in 5 patients. In one patient, a single lesion could not be detected on the follow-up scan. No appreciable change in lesion size and vessel-lesion relationship was observed at follow up. All lesions demonstrated hyperintense signal intensity on GRE-T2* weighted images and isointense signal on QSM at both time points. Therefore, these lesions were considered as non-associated with iron pathology. Additionally, no significant change in brain volume was observed: fBPV 0.78 ± 0.06 at baseline vs. 0.77 ± 0.05 at follow up, p>0.05.
CONCLUSION: Cerebral lesions in NMOSD patients remain 'inert' and do not show any substantial variations in morphological characteristics during a 2-3-year follow-up period.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  7T Magnetic resonance imaging; Follow-up; Neuromyelitis optica spectrum disorder; Quantitative susceptibility mapping; Susceptibility weighted imaging

Year:  2020        PMID: 32272444      PMCID: PMC7410392          DOI: 10.1016/j.msard.2020.102066

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  44 in total

Review 1.  Alternative activation of macrophages: an immunologic functional perspective.

Authors:  Fernando O Martinez; Laura Helming; Siamon Gordon
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

2.  A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.

Authors:  Vanda A Lennon; Dean M Wingerchuk; Thomas J Kryzer; Sean J Pittock; Claudia F Lucchinetti; Kazuo Fujihara; Ichiro Nakashima; Brian G Weinshenker
Journal:  Lancet       Date:  2004 Dec 11-17       Impact factor: 79.321

3.  Brain abnormalities in neuromyelitis optica.

Authors:  Sean J Pittock; Vanda A Lennon; Karl Krecke; Dean M Wingerchuk; Claudia F Lucchinetti; Brian G Weinshenker
Journal:  Arch Neurol       Date:  2006-03

Review 4.  A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitis optica.

Authors:  Anand Iyer; Liene Elsone; Richard Appleton; Anu Jacob
Journal:  Autoimmunity       Date:  2014-02-10       Impact factor: 2.815

Review 5.  The spectrum of neuromyelitis optica.

Authors:  Dean M Wingerchuk; Vanda A Lennon; Claudia F Lucchinetti; Sean J Pittock; Brian G Weinshenker
Journal:  Lancet Neurol       Date:  2007-09       Impact factor: 44.182

Review 6.  Magnetic resonance imaging in neuromyelitis optica.

Authors:  George Tackley; Wilhelm Kuker; Jacqueline Palace
Journal:  Mult Scler       Date:  2014-05-14       Impact factor: 6.312

7.  White matter spectroscopy in neuromyelitis optica: a case control study.

Authors:  Denis Bernardi Bichuetti; René Leandro Magalhães Rivero; Enedina Maria Lobato de Oliveira; Daniel May Oliveira; Nilton Amorin de Souza; Roberto Gomes Nogueira; Nitamar Abdala; Alberto Gabbai
Journal:  J Neurol       Date:  2009-01-22       Impact factor: 4.849

8.  Ultrahigh-Field MR (7 T) Imaging of Brain Lesions in Neuromyelitis Optica.

Authors:  Ilya Kister; Joseph Herbert; Yongxia Zhou; Yulin Ge
Journal:  Mult Scler Int       Date:  2013-01-27

9.  Diffuse white matter damage is absent in neuromyelitis optica.

Authors:  F Aboul-Enein; M Krssák; R Höftberger; D Prayer; W Kristoferitsch
Journal:  AJNR Am J Neuroradiol       Date:  2009-09-12       Impact factor: 4.966

10.  Neuromyelitis optica does not impact periventricular venous density versus healthy controls: a 7.0 Tesla MRI clinical study.

Authors:  Sophie Schumacher; Florence Pache; Judith Bellmann-Strobl; Janina Behrens; Petr Dusek; Lutz Harms; Klemens Ruprecht; Petra Nytrova; Sanjeev Chawla; Thoralf Niendorf; Ilya Kister; Friedemann Paul; Yulin Ge; Jens Wuerfel; Tim Sinnecker
Journal:  MAGMA       Date:  2016-04-12       Impact factor: 2.533

View more
  1 in total

Review 1.  Magnetic resonance imaging in neuromyelitis optica spectrum disorder.

Authors:  Laura Clarke; Simon Arnett; Kate Lilley; Jacky Liao; Sandeep Bhuta; Simon A Broadley
Journal:  Clin Exp Immunol       Date:  2021-07-06       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.